DK2454266T3 - 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaen-citratsalt - Google Patents

9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaen-citratsalt

Info

Publication number
DK2454266T3
DK2454266T3 DK10737645.1T DK10737645T DK2454266T3 DK 2454266 T3 DK2454266 T3 DK 2454266T3 DK 10737645 T DK10737645 T DK 10737645T DK 2454266 T3 DK2454266 T3 DK 2454266T3
Authority
DK
Denmark
Prior art keywords
nonaen
hexacosa
trioxa
tetracyclo
triaza
Prior art date
Application number
DK10737645.1T
Other languages
Danish (da)
English (en)
Inventor
Brian Dymock
Cheng Hsia Angeline Lee
Anthony Deodaunia William
Original Assignee
Cell Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapeutics Inc filed Critical Cell Therapeutics Inc
Application granted granted Critical
Publication of DK2454266T3 publication Critical patent/DK2454266T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK10737645.1T 2009-07-15 2010-07-14 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaen-citratsalt DK2454266T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22560909P 2009-07-15 2009-07-15
PCT/SG2010/000265 WO2011008172A1 (en) 2009-07-15 2010-07-14 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt

Publications (1)

Publication Number Publication Date
DK2454266T3 true DK2454266T3 (da) 2013-09-08

Family

ID=42790728

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10737645.1T DK2454266T3 (da) 2009-07-15 2010-07-14 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaen-citratsalt

Country Status (18)

Country Link
US (1) US9062074B2 (enExample)
EP (1) EP2454266B1 (enExample)
JP (2) JP6013911B2 (enExample)
CN (1) CN102762577B (enExample)
AR (2) AR077483A1 (enExample)
BR (1) BR112012000750B1 (enExample)
CA (1) CA2768210C (enExample)
DK (1) DK2454266T3 (enExample)
ES (1) ES2429525T3 (enExample)
HR (1) HRP20130941T1 (enExample)
MX (1) MX2012000680A (enExample)
PL (1) PL2454266T3 (enExample)
PT (1) PT2454266E (enExample)
RU (1) RU2543721C2 (enExample)
SI (1) SI2454266T1 (enExample)
SM (1) SMT201300112B (enExample)
TW (1) TWI537276B (enExample)
WO (1) WO2011008172A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2966753A1 (en) 2014-11-17 2016-05-26 Arno Therapeutics, Inc. Onapristone extended-release compositions and methods
AU2016326657B2 (en) 2015-09-25 2019-10-24 Context Biopharma, Inc. Methods of making onapristone intermediates
CA3008422A1 (en) 2015-12-15 2017-06-22 Context Biopharma Inc. Amorphous onapristone compositions and methods of making the same
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY110603A (en) * 1993-05-27 1998-08-29 Novartis Ag Tetrahydropyran derivatives
US7151096B2 (en) * 2003-03-05 2006-12-19 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
CN101365703B (zh) * 2005-11-16 2013-11-06 S*Bio私人有限公司 杂烷基连接的嘧啶衍生物

Also Published As

Publication number Publication date
CN102762577A (zh) 2012-10-31
AR114987A2 (es) 2020-11-11
EP2454266A1 (en) 2012-05-23
JP2012533539A (ja) 2012-12-27
WO2011008172A1 (en) 2011-01-20
CA2768210C (en) 2017-08-15
ES2429525T3 (es) 2013-11-15
PL2454266T3 (pl) 2014-01-31
AR077483A1 (es) 2011-08-31
HRP20130941T1 (hr) 2013-11-08
MX2012000680A (es) 2012-02-28
BR112012000750A8 (pt) 2018-02-06
TWI537276B (zh) 2016-06-11
EP2454266B1 (en) 2013-07-10
CA2768210A1 (en) 2011-01-20
SI2454266T1 (sl) 2013-10-30
BR112012000750B1 (pt) 2021-05-25
BR112012000750A2 (pt) 2016-08-09
SMT201300112B (it) 2013-11-08
JP2015164941A (ja) 2015-09-17
US9062074B2 (en) 2015-06-23
RU2012105044A (ru) 2013-08-20
HK1178159A1 (en) 2013-09-06
TW201107336A (en) 2011-03-01
US20120196876A1 (en) 2012-08-02
RU2543721C2 (ru) 2015-03-10
JP6013911B2 (ja) 2016-10-25
CN102762577B (zh) 2015-01-07
PT2454266E (pt) 2013-10-10

Similar Documents

Publication Publication Date Title
NL301021I2 (nl) talazoparib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout.
AP2012006216A0 (en) Benzimidazole-imidazole derivatives.
AP2011005788A0 (en) Sulfonamide derivatives.
BRPI1011414A2 (pt) "método."
PL2531492T3 (pl) Pochodne 1,2,4-triazyno-4-aminy
AP2012006192A0 (en) PyrroloÄ2,3-DÜ pyrimidine compounds.
BR112012003704A2 (pt) derivados de 3-amino-5-fenil-5,6-di-hidro-2h[1,4]oxazina
BRPI0919948A2 (pt) Pirido[4,3-b]indois contendo porções rígidas
BRPI1006113A2 (pt) "derivado de piridina".
HRP20150107T1 (xx) Derivati dioksabiciklo[3.2.1]oktan-2,3,4-triola
BRPI1106091A2 (pt) "método de solda."
UY33125A (es) Diaza-espiro-[5,5]-undecanos
ZA201206630B (en) Hetaryl-[1,8]naphthyridine derivatives
ZA201404074B (en) 6-difluoromethyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives
BRPI0917446A2 (pt) derivados de acilaminobenzamida.
ZA201204135B (en) 3,4,4a,10b-tetrahydro-1h-thiopyrano-[4.3-c]isoquinoline derivatives
BRPI1016192A2 (pt) derivados de soxazol.
DK2442870T3 (da) Pyrazinooxazepin-derivater.
IL289379A (en) Citrate salt of 11-(2-pyrrolidin-1-yl-ethoxy)-19,14-dioxa-26,7,5-triaza-tetracyclo[1.1.3.19(6,2)1(12,8)]hepatacosa- 1(25),2(26),12,10,8,5,3(27)j23,21,16–Decan
ZA201302112B (en) 1,4-oxazepane derivatives
BRPI1011014A2 (pt) método de produção.
IT1397021B1 (it) Carrello per rimorchi.
DK2454266T3 (da) 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaen-citratsalt
AP2010005479A0 (en) Phospohorous pentoxide producing methods.
BR112013011418A8 (pt) derivado de pirazino [2,3-d] isoxadol